

GLAXOSMITHKLINE PLC  
Form 6-K  
July 11, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending July 11, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or  
Connected Persons**

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan notified the Company and the under-mentioned person on 11

July 2008 of changes to his interests in Ordinary shares ADRs arising from an increase in his interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on 10 July 2008 at a price of \$ 48.40

per ADR :-

Dr D Pulman 24.40

This notification relates to a transaction notified in accordance with

Disclosure and Transparency Rule 3.1.4R(1)(a)

S M Bicknell  
Company Secretary

11  
July  
2008

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: July 11, 2008

By: VICTORIA WHYTE  
-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc